Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of ...
JD Supra8 天
DOJ and CISA Issue Proposed Rules Regulating Export of Bulk Sensitive Data
The Department of Justice (DOJ) released a Final Rule restricting certain transfers of Americans’ sensitive personal data to identified countries ...
Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S ...
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced Allergan Medical Institute (AMI) will open three new ...
BMJ20 天
The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of ...
11 Hospital for Special Surgery, New York, New York, USA Correspondence to Dr Vivian P Bykerk, Hospital for Special Surgery, 535 East 70th St., New York, NY 10021, USA; bykerkv{at}hss.edu Objective To ...
ascopubs.org26 天
Global Equity in Clinical Trials: A Pragmatic Approach
Lack of funding and hesitancy of industry to conduct clinical trials in SSA 2. Lack of access to standard-of-care cancer medications 1. Conduct phase IV postmarketing trials with already established ...
Federal Register27 天
Nonprescription Drug Product With an Additional Condition for Nonprescription Use
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...